BR112015028644A2 - composições de cenicriviroc e métodos de criação e uso do mesmo - Google Patents
composições de cenicriviroc e métodos de criação e uso do mesmoInfo
- Publication number
- BR112015028644A2 BR112015028644A2 BR112015028644A BR112015028644A BR112015028644A2 BR 112015028644 A2 BR112015028644 A2 BR 112015028644A2 BR 112015028644 A BR112015028644 A BR 112015028644A BR 112015028644 A BR112015028644 A BR 112015028644A BR 112015028644 A2 BR112015028644 A2 BR 112015028644A2
- Authority
- BR
- Brazil
- Prior art keywords
- approximately
- cenicriviroc
- salt
- composition
- weight
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 111
- PNDKCRDVVKJPKG-WHERJAGFSA-N cenicriviroc Chemical compound C1=CC(OCCOCCCC)=CC=C1C1=CC=C(N(CC(C)C)CCC\C(=C/2)C(=O)NC=3C=CC(=CC=3)[S@@](=O)CC=3N(C=NC=3)CCC)C\2=C1 PNDKCRDVVKJPKG-WHERJAGFSA-N 0.000 title abstract 101
- 229950011033 cenicriviroc Drugs 0.000 title abstract 101
- 238000000034 method Methods 0.000 title abstract 11
- 150000003839 salts Chemical class 0.000 abstract 65
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 46
- 239000001530 fumaric acid Substances 0.000 abstract 23
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 abstract 23
- 229960001627 lamivudine Drugs 0.000 abstract 23
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 23
- 239000000945 filler Substances 0.000 abstract 21
- 239000008194 pharmaceutical composition Substances 0.000 abstract 16
- 239000013543 active substance Substances 0.000 abstract 13
- 239000007884 disintegrant Substances 0.000 abstract 12
- 238000009472 formulation Methods 0.000 abstract 11
- 239000000314 lubricant Substances 0.000 abstract 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 8
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 8
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 abstract 7
- 229960003804 efavirenz Drugs 0.000 abstract 7
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 abstract 7
- 239000008187 granular material Substances 0.000 abstract 7
- 235000012054 meals Nutrition 0.000 abstract 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract 6
- 239000002274 desiccant Substances 0.000 abstract 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 6
- 229920002785 Croscarmellose sodium Polymers 0.000 abstract 5
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 5
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 abstract 5
- 239000010410 layer Substances 0.000 abstract 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 5
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 5
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 4
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 abstract 4
- -1 e.g. Substances 0.000 abstract 4
- 230000006698 induction Effects 0.000 abstract 4
- 235000019359 magnesium stearate Nutrition 0.000 abstract 4
- 239000007787 solid Substances 0.000 abstract 4
- IXPBPUPDRDCRSY-WNRKZQPVSA-N (5e)-8-[4-(2-butoxyethoxy)phenyl]-1-(2-methylpropyl)-n-[4-[(3-propylimidazol-4-yl)methylsulfinyl]phenyl]-3,4-dihydro-2h-1-benzazocine-5-carboxamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC(OCCOCCCC)=CC=C1C1=CC=C(N(CC(C)C)CCC\C(=C/2)C(=O)NC=3C=CC(=CC=3)[S+]([O-])CC=3N(C=NC=3)CCC)C\2=C1 IXPBPUPDRDCRSY-WNRKZQPVSA-N 0.000 abstract 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 3
- 229930195725 Mannitol Natural products 0.000 abstract 3
- 229920002472 Starch Polymers 0.000 abstract 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 3
- 229930006000 Sucrose Natural products 0.000 abstract 3
- 241000700605 Viruses Species 0.000 abstract 3
- 229910000019 calcium carbonate Inorganic materials 0.000 abstract 3
- 235000010216 calcium carbonate Nutrition 0.000 abstract 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 abstract 3
- 229920002678 cellulose Polymers 0.000 abstract 3
- 239000001913 cellulose Substances 0.000 abstract 3
- 235000010980 cellulose Nutrition 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 235000019700 dicalcium phosphate Nutrition 0.000 abstract 3
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 abstract 3
- 239000012535 impurity Substances 0.000 abstract 3
- 239000008101 lactose Substances 0.000 abstract 3
- 239000000594 mannitol Substances 0.000 abstract 3
- 235000010355 mannitol Nutrition 0.000 abstract 3
- 239000002356 single layer Substances 0.000 abstract 3
- 239000000600 sorbitol Substances 0.000 abstract 3
- 235000010356 sorbitol Nutrition 0.000 abstract 3
- 229940032147 starch Drugs 0.000 abstract 3
- 239000008107 starch Substances 0.000 abstract 3
- 235000019698 starch Nutrition 0.000 abstract 3
- 239000005720 sucrose Substances 0.000 abstract 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 abstract 2
- 102000006395 Globulins Human genes 0.000 abstract 2
- 108010044091 Globulins Proteins 0.000 abstract 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 abstract 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 235000021355 Stearic acid Nutrition 0.000 abstract 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 230000008901 benefit Effects 0.000 abstract 2
- 239000008380 degradant Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000007908 dry granulation Methods 0.000 abstract 2
- 235000013305 food Nutrition 0.000 abstract 2
- 239000013022 formulation composition Substances 0.000 abstract 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
- 239000005414 inactive ingredient Substances 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 229960000485 methotrexate Drugs 0.000 abstract 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 abstract 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 abstract 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 abstract 2
- 239000000377 silicon dioxide Substances 0.000 abstract 2
- 229940080313 sodium starch Drugs 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- 239000008117 stearic acid Substances 0.000 abstract 2
- 229960001967 tacrolimus Drugs 0.000 abstract 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 abstract 2
- 239000000454 talc Substances 0.000 abstract 2
- 229910052623 talc Inorganic materials 0.000 abstract 2
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 abstract 1
- 108010019625 Atazanavir Sulfate Proteins 0.000 abstract 1
- 102000004274 CCR5 Receptors Human genes 0.000 abstract 1
- 108010017088 CCR5 Receptors Proteins 0.000 abstract 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
- 108010036949 Cyclosporine Proteins 0.000 abstract 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 abstract 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 abstract 1
- 102000006992 Interferon-alpha Human genes 0.000 abstract 1
- 108010047761 Interferon-alpha Proteins 0.000 abstract 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 abstract 1
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 abstract 1
- 240000007594 Oryza sativa Species 0.000 abstract 1
- 235000007164 Oryza sativa Nutrition 0.000 abstract 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 abstract 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 abstract 1
- 244000269722 Thea sinensis Species 0.000 abstract 1
- 229960004748 abacavir Drugs 0.000 abstract 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 abstract 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000000781 anti-lymphocytic effect Effects 0.000 abstract 1
- 230000000798 anti-retroviral effect Effects 0.000 abstract 1
- 229960003277 atazanavir Drugs 0.000 abstract 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 abstract 1
- 229960002170 azathioprine Drugs 0.000 abstract 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 abstract 1
- 229960004669 basiliximab Drugs 0.000 abstract 1
- 235000013361 beverage Nutrition 0.000 abstract 1
- 229950002892 bevirimat Drugs 0.000 abstract 1
- YJEJKUQEXFSVCJ-WRFMNRASSA-N bevirimat Chemical compound C1C[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C YJEJKUQEXFSVCJ-WRFMNRASSA-N 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 229960001265 ciclosporin Drugs 0.000 abstract 1
- 229960002402 cobicistat Drugs 0.000 abstract 1
- ZCIGNRJZKPOIKD-CQXVEOKZSA-N cobicistat Chemical compound S1C(C(C)C)=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SC=NC=2)CC=2C=CC=CC=2)=C1 ZCIGNRJZKPOIKD-CQXVEOKZSA-N 0.000 abstract 1
- 229960001681 croscarmellose sodium Drugs 0.000 abstract 1
- 229930182912 cyclosporin Natural products 0.000 abstract 1
- 229960002806 daclizumab Drugs 0.000 abstract 1
- 229960005107 darunavir Drugs 0.000 abstract 1
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 abstract 1
- 230000000593 degrading effect Effects 0.000 abstract 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 abstract 1
- 229960002542 dolutegravir Drugs 0.000 abstract 1
- RHWKPHLQXYSBKR-BMIGLBTASA-N dolutegravir Chemical compound C([C@@H]1OCC[C@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F RHWKPHLQXYSBKR-BMIGLBTASA-N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229960003586 elvitegravir Drugs 0.000 abstract 1
- JUZYLCPPVHEVSV-LJQANCHMSA-N elvitegravir Chemical compound COC1=CC=2N([C@H](CO)C(C)C)C=C(C(O)=O)C(=O)C=2C=C1CC1=CC=CC(Cl)=C1F JUZYLCPPVHEVSV-LJQANCHMSA-N 0.000 abstract 1
- 229960000366 emtricitabine Drugs 0.000 abstract 1
- 229960005167 everolimus Drugs 0.000 abstract 1
- 235000020937 fasting conditions Nutrition 0.000 abstract 1
- 235000015203 fruit juice Nutrition 0.000 abstract 1
- 229960000890 hydrocortisone Drugs 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 229940124524 integrase inhibitor Drugs 0.000 abstract 1
- 239000002850 integrase inhibitor Substances 0.000 abstract 1
- 229950000038 interferon alfa Drugs 0.000 abstract 1
- 229960004525 lopinavir Drugs 0.000 abstract 1
- 235000004213 low-fat Nutrition 0.000 abstract 1
- GSNHKUDZZFZSJB-QYOOZWMWSA-N maraviroc Chemical compound CC(C)C1=NN=C(C)N1[C@@H]1C[C@H](N2CC[C@H](NC(=O)C3CCC(F)(F)CC3)C=3C=CC=CC=3)CC[C@H]2C1 GSNHKUDZZFZSJB-QYOOZWMWSA-N 0.000 abstract 1
- 229960004710 maraviroc Drugs 0.000 abstract 1
- 230000035800 maturation Effects 0.000 abstract 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 abstract 1
- 229960000951 mycophenolic acid Drugs 0.000 abstract 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 abstract 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 abstract 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 239000003002 pH adjusting agent Substances 0.000 abstract 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 1
- 229960005205 prednisolone Drugs 0.000 abstract 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 229960004742 raltegravir Drugs 0.000 abstract 1
- CZFFBEXEKNGXKS-UHFFFAOYSA-N raltegravir Chemical compound O1C(C)=NN=C1C(=O)NC(C)(C)C1=NC(C(=O)NCC=2C=CC(F)=CC=2)=C(O)C(=O)N1C CZFFBEXEKNGXKS-UHFFFAOYSA-N 0.000 abstract 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 235000009566 rice Nutrition 0.000 abstract 1
- 229960002814 rilpivirine Drugs 0.000 abstract 1
- YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 abstract 1
- 229960000311 ritonavir Drugs 0.000 abstract 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 abstract 1
- 229960004641 rituximab Drugs 0.000 abstract 1
- 229960002930 sirolimus Drugs 0.000 abstract 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 1
- 239000007909 solid dosage form Substances 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
- 229960004556 tenofovir Drugs 0.000 abstract 1
- 229960001355 tenofovir disoproxil Drugs 0.000 abstract 1
- JFVZFKDSXNQEJW-CQSZACIVSA-N tenofovir disoproxil Chemical compound N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N JFVZFKDSXNQEJW-CQSZACIVSA-N 0.000 abstract 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 241001430294 unidentified retrovirus Species 0.000 abstract 1
- 229960002555 zidovudine Drugs 0.000 abstract 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Virology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361823766P | 2013-05-15 | 2013-05-15 | |
| PCT/US2014/038211 WO2014186581A1 (en) | 2013-05-15 | 2014-05-15 | Cenicriviroc compositions and methods of making and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015028644A2 true BR112015028644A2 (pt) | 2017-07-25 |
Family
ID=51898872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015028644A BR112015028644A2 (pt) | 2013-05-15 | 2014-05-15 | composições de cenicriviroc e métodos de criação e uso do mesmo |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20160081985A1 (enExample) |
| EP (1) | EP2996694A4 (enExample) |
| JP (1) | JP6391674B2 (enExample) |
| KR (1) | KR20160013068A (enExample) |
| CN (1) | CN105263498B (enExample) |
| AU (1) | AU2014265327B2 (enExample) |
| BR (1) | BR112015028644A2 (enExample) |
| CA (1) | CA2911212A1 (enExample) |
| CL (1) | CL2015003346A1 (enExample) |
| IL (1) | IL242394B (enExample) |
| MX (1) | MX383706B (enExample) |
| MY (1) | MY180145A (enExample) |
| PH (1) | PH12015502539A1 (enExample) |
| RU (1) | RU2633069C2 (enExample) |
| SG (2) | SG10201708595YA (enExample) |
| UA (1) | UA115807C2 (enExample) |
| WO (1) | WO2014186581A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR034985A1 (es) | 2001-08-08 | 2004-03-24 | Takeda Chemical Industries Ltd | Compuesto biciclico; produccion y uso del mismo |
| BR112016021682A2 (pt) * | 2014-03-21 | 2018-06-26 | Tobira Therapeutics, Inc. | cenicriviroc para o tratamento da fibrose |
| SG10201902137PA (en) * | 2014-09-12 | 2019-04-29 | Tobira Therapeutics Inc | Cenicriviroc combination therapy for the treatment of fibrosis |
| KR20170097735A (ko) * | 2014-12-23 | 2017-08-28 | 토비라 쎄라퓨틱스, 인크. | 세니크리비록 및 관련된 유사체들을 만드는 공정 |
| AU2015382376B2 (en) * | 2015-02-10 | 2021-07-01 | Tobira Therapeutics, Inc. | Cenicriviroc for the treatment of fibrosis |
| WO2016135740A1 (en) * | 2015-02-23 | 2016-09-01 | Natco Pharma Limited | Process for preparing stable oral compositions of everolimus |
| CA2998509A1 (en) * | 2015-09-16 | 2017-03-23 | Tobira Therapeutics, Inc. | Cenicriviroc combination therapy for the treatment of fibrosis |
| SG11201811140UA (en) * | 2016-06-21 | 2019-01-30 | Tobira Therapeutics Inc | Purified cenicriviroc and purified intermediates for making cenicriviroc |
| EP3496718A4 (en) * | 2016-08-08 | 2020-01-22 | Hetero Labs Limited | ANTIRETROVIRAL COMPOSITIONS |
| SG11201901438VA (en) | 2016-08-31 | 2019-03-28 | Tobira Therapeutics Inc | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate |
| US10736905B1 (en) | 2016-09-09 | 2020-08-11 | Shahin Fatholahi | Nefopam dosage forms and methods of treatment |
| SG11201910191RA (en) | 2017-05-11 | 2019-11-28 | Univ King Abdullah Sci & Tech | A peptide capable of forming a gel for use in tissue engineering and bioprinting |
| EP4215600A1 (en) | 2017-05-11 | 2023-07-26 | King Abdullah University of Science and Technology | Device and method for microfluidics-based 3d bioprinting |
| RU2662160C9 (ru) * | 2017-07-03 | 2018-10-22 | Александрович Иващенко Андрей | Комбинированный лекарственный препарат для терапии вирусных инфекций |
| US11446311B2 (en) | 2017-09-08 | 2022-09-20 | Shahin Fatholahi | Methods for treating pain associated with sickle cell disease |
| US10736874B1 (en) | 2017-09-08 | 2020-08-11 | Shahin Fatholahi | Methods for treating pain associated with sickle cell disease |
| WO2021133811A1 (en) * | 2019-12-26 | 2021-07-01 | Teva Pharmaceuticals International Gmbh | Solid state forms of cenicriviroc and process for preparation thereof |
| EP4093380A1 (en) | 2020-01-23 | 2022-11-30 | Lupin Limited | Pharmaceutical compositions of raltegravir |
| US12109327B2 (en) | 2020-08-20 | 2024-10-08 | King Abdullah University Of Science And Technology | Scaffolds from self-assembling tetrapeptides support 3D spreading, osteogenic differentiation and angiogenesis of mesenchymal stem cells |
| US11673324B2 (en) | 2020-08-20 | 2023-06-13 | King Abdullah University Of Science And Technology | Nozzle for 3D bioprinting |
| JP2022108727A (ja) * | 2021-01-13 | 2022-07-26 | 日曹商事株式会社 | フマル酸含有固形製剤 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2167649C2 (ru) * | 1995-08-11 | 2001-05-27 | Ниссан Кемикал Индастриз, Лтд. | Способ получения твердой дисперсии умеренно водорастворимого лекарственного вещества (варианты) и фармацевтическая композиция |
| JP3995414B2 (ja) * | 1997-10-20 | 2007-10-24 | 大日本住友製薬株式会社 | 安定な医薬組成物 |
| CA2244097A1 (en) * | 1998-08-21 | 2000-02-21 | Bernard Charles Sherman | Pharmaceutical composition comprising bupropion hydrochloride and fumaric acid |
| US6858230B1 (en) * | 1999-04-12 | 2005-02-22 | Shionogi & Co., Ltd. | Process for producing medicinal composition of basic hydrophobic medicinal compound |
| JPWO2006059716A1 (ja) * | 2004-12-03 | 2008-06-05 | 武田薬品工業株式会社 | 固形製剤 |
| MA34215B1 (fr) * | 2010-04-02 | 2013-05-02 | Phivco 1 Llc | Traitement d'association comprenant un antagoniste du récepteur ccr5, un inhibiteur de la protéase du vih-1 et un accélérateur pharmacocinétique |
| BR112016021682A2 (pt) * | 2014-03-21 | 2018-06-26 | Tobira Therapeutics, Inc. | cenicriviroc para o tratamento da fibrose |
-
2014
- 2014-05-15 RU RU2014150327A patent/RU2633069C2/ru active
- 2014-05-15 BR BR112015028644A patent/BR112015028644A2/pt not_active Application Discontinuation
- 2014-05-15 AU AU2014265327A patent/AU2014265327B2/en not_active Ceased
- 2014-05-15 MX MX2015015500A patent/MX383706B/es unknown
- 2014-05-15 EP EP14797645.0A patent/EP2996694A4/en not_active Withdrawn
- 2014-05-15 UA UAA201512359A patent/UA115807C2/uk unknown
- 2014-05-15 WO PCT/US2014/038211 patent/WO2014186581A1/en not_active Ceased
- 2014-05-15 CA CA2911212A patent/CA2911212A1/en not_active Abandoned
- 2014-05-15 CN CN201480027717.3A patent/CN105263498B/zh active Active
- 2014-05-15 JP JP2016514093A patent/JP6391674B2/ja not_active Expired - Fee Related
- 2014-05-15 KR KR1020157035069A patent/KR20160013068A/ko not_active Ceased
- 2014-05-15 SG SG10201708595YA patent/SG10201708595YA/en unknown
- 2014-05-15 SG SG11201509136YA patent/SG11201509136YA/en unknown
- 2014-05-15 US US14/891,019 patent/US20160081985A1/en not_active Abandoned
- 2014-05-15 MY MYPI2015703958A patent/MY180145A/en unknown
-
2015
- 2015-11-02 IL IL242394A patent/IL242394B/en active IP Right Grant
- 2015-11-05 PH PH12015502539A patent/PH12015502539A1/en unknown
- 2015-11-13 CL CL2015003346A patent/CL2015003346A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014265327A1 (en) | 2015-11-26 |
| KR20160013068A (ko) | 2016-02-03 |
| PH12015502539B1 (en) | 2016-02-22 |
| CA2911212A1 (en) | 2014-11-20 |
| SG11201509136YA (en) | 2015-12-30 |
| WO2014186581A1 (en) | 2014-11-20 |
| CN105263498A (zh) | 2016-01-20 |
| IL242394B (en) | 2019-05-30 |
| PH12015502539A1 (en) | 2016-02-22 |
| HK1214171A1 (zh) | 2016-07-22 |
| RU2633069C2 (ru) | 2017-10-11 |
| CL2015003346A1 (es) | 2016-09-16 |
| JP6391674B2 (ja) | 2018-09-19 |
| SG10201708595YA (en) | 2017-11-29 |
| MX2015015500A (es) | 2016-08-11 |
| RU2014150327A (ru) | 2016-07-10 |
| EP2996694A1 (en) | 2016-03-23 |
| UA115807C2 (uk) | 2017-12-26 |
| MY180145A (en) | 2020-11-23 |
| US20160081985A1 (en) | 2016-03-24 |
| CN105263498B (zh) | 2019-04-26 |
| NZ713981A (en) | 2021-03-26 |
| MX383706B (es) | 2025-03-14 |
| AU2014265327B2 (en) | 2019-08-15 |
| EP2996694A4 (en) | 2016-12-07 |
| JP2016518452A (ja) | 2016-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015028644A2 (pt) | composições de cenicriviroc e métodos de criação e uso do mesmo | |
| BR112021010847A2 (pt) | Antagonista de receptor de crf1, formulações farmacêuticas e formas sólidas das mesmas para o tratamento de hiperplasia adrenal congênita | |
| BR112013012245B1 (pt) | Comprimido compreendendo hcl de rilpivirina e fumarato de tenofovir disoproxila seu uso no tratamento profilático ou terapêutico de uma infecção por hiv | |
| IL298901A (en) | Crf1 receptor antagonist for the treatment of congenital adrenal hyperplasia | |
| KR20200038951A (ko) | 코티코트로핀 방출 인자 수용체 길항제 | |
| BR112014000290B1 (pt) | Forma de dosagem oral de combinação de darunavir, processo para preparação de uma forma de dosagem oral e uso de granulado de darunavir | |
| US20190358240A1 (en) | Hiv treatment formulation of atazanavir and cobicistat | |
| CA3230291A1 (en) | Dosing regimens associated with extended release paliperidone injectable formulations | |
| BRPI0620865A2 (pt) | métodos para melhorar a farmacocinética de inibidores das integrases do hiv | |
| TWI830703B (zh) | 組合物及其用途和治療 | |
| CN103550214A (zh) | 用于口服药剂的稳定脂质组合物 | |
| JP2020536931A (ja) | 二層医薬錠剤製剤 | |
| EP4541353A1 (en) | Pharmaceutical composition for treating and resisting blood coagulation and use thereof | |
| EP3496718A1 (en) | Anti-retroviral compositions | |
| EP3496719B1 (en) | A multi-class anti-retroviral composition | |
| US20150141376A1 (en) | Pharmaceutical compositions of anti-viral compounds and process for preparation thereof | |
| TW201434464A (zh) | 藥物 | |
| Lee et al. | Pharmacokinetics of a telmisartan, amlodipine and hydrochlorothiazide fixed-dose combination: A replicate crossover study in healthy Korean male subjects | |
| EP3496710A1 (en) | A high drug loaded tablet composition for treating hiv | |
| CN112843053A (zh) | Ns5a抑制剂组合物 | |
| JP2024124514A (ja) | 医薬品 | |
| Pa et al. | Optimization of Olanzapine mouth dissolving tablets using micronization | |
| HK40002830A (en) | Hiv treatment formulation of atazanavir and cobicistat | |
| JP2005281268A (ja) | 経時安定な抗ヒスタミン類固形製剤 | |
| WO2014193589A1 (en) | Cancer treatment method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: TOBIRA THERAPEUTICS, INC. (US) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |